Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Accounts Payables (2016 - 2026)

Angiodynamics' Accounts Payables history spans 16 years, with the latest figure at $29.1 million for Q1 2026.

  • For Q1 2026, Accounts Payables fell 3.83% year-over-year to $29.1 million; the TTM value through Feb 2026 reached $29.1 million, down 3.83%, while the annual FY2025 figure was $33.3 million, 11.81% down from the prior year.
  • Accounts Payables reached $29.1 million in Q1 2026 per ANGO's latest filing, down from $35.4 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $40.4 million in Q2 2023 to a low of $21.6 million in Q1 2022.
  • Average Accounts Payables over 5 years is $32.4 million, with a median of $33.3 million recorded in 2025.
  • The largest YoY upside for Accounts Payables was 65.04% in 2023 against a maximum downside of 15.21% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $34.7 million in 2022, then rose by 8.54% to $37.6 million in 2023, then dropped by 7.71% to $34.7 million in 2024, then grew by 1.85% to $35.4 million in 2025, then decreased by 17.76% to $29.1 million in 2026.
  • Per Business Quant, the three most recent readings for ANGO's Accounts Payables are $29.1 million (Q1 2026), $35.4 million (Q4 2025), and $31.9 million (Q3 2025).